Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HDAC8_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HDAC8_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HDAC8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HDAC8_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HDAC8_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HDAC8_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
GO:003220417 | Esophagus | ESCC | regulation of telomere maintenance | 65/8552 | 80/18723 | 6.02e-11 | 1.90e-09 | 65 |
GO:003450211 | Esophagus | ESCC | protein localization to chromosome | 70/8552 | 92/18723 | 2.54e-09 | 5.64e-08 | 70 |
GO:0031397111 | Esophagus | ESCC | negative regulation of protein ubiquitination | 63/8552 | 83/18723 | 1.87e-08 | 3.65e-07 | 63 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
GO:1903321111 | Esophagus | ESCC | negative regulation of protein modification by small protein conjugation or removal | 69/8552 | 95/18723 | 8.54e-08 | 1.44e-06 | 69 |
GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
GO:00165754 | Esophagus | ESCC | histone deacetylation | 60/8552 | 82/18723 | 3.85e-07 | 5.32e-06 | 60 |
GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
GO:003220014 | Esophagus | ESCC | telomere organization | 99/8552 | 159/18723 | 1.77e-05 | 1.57e-04 | 99 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC8 | SNV | Missense_Mutation | | c.1106T>A | p.Ile369Asn | p.I369N | Q9BY41 | protein_coding | deleterious(0) | benign(0.388) | TCGA-A2-A0YF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Arimidex | SD |
HDAC8 | SNV | Missense_Mutation | | c.463N>G | p.Leu155Val | p.L155V | Q9BY41 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
HDAC8 | SNV | Missense_Mutation | rs397515417 | c.932N>T | p.Thr311Met | p.T311M | Q9BY41 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
HDAC8 | insertion | In_Frame_Ins | novel | c.365_366insAAGATATATTGTTTCCCCTACCAAGTTTGAAAAAGATTCTTT | p.Ala122_Ala123insArgTyrIleValSerProThrLysPheGluLysAspSerPhe | p.A122_A123insRYIVSPTKFEKDSF | Q9BY41 | protein_coding | | | TCGA-A7-A0CD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HDAC8 | insertion | Nonsense_Mutation | novel | c.141_142insGGAGAATCGCTTGAACCCCGGAGGTGAAGG | p.Ala47_Tyr48insGlyGluSerLeuGluProArgArgTerArg | p.A47_Y48insGESLEPRR*R | Q9BY41 | protein_coding | | | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
HDAC8 | SNV | Missense_Mutation | novel | c.926N>T | p.Ala309Val | p.A309V | Q9BY41 | protein_coding | tolerated(0.19) | benign(0.076) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC8 | SNV | Missense_Mutation | | c.567N>G | p.Phe189Leu | p.F189L | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HDAC8 | SNV | Missense_Mutation | novel | c.425A>G | p.His142Arg | p.H142R | Q9BY41 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HDAC8 | SNV | Missense_Mutation | | c.170T>G | p.Val57Gly | p.V57G | Q9BY41 | protein_coding | deleterious(0) | possibly_damaging(0.623) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC8 | SNV | Missense_Mutation | novel | c.616N>A | p.Gly206Arg | p.G206R | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID29671355-Compound-67 | | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051799 | DACINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID29671355-Compound-37 | | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | PCI-24781 | ABEXINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PHENYLBUTANOIC ACID | PHENYLBUTANOIC ACID | 24044874 |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | VORINOSTAT | VORINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | PANOBINOSTAT | PANOBINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PHENYLBUTYRYLHYDROXAMIC ACID | PHENYLBUTYRYLHYDROXAMIC ACID | 21874153 |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID29671355-Compound-25 | | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051793 | GIVINOSTAT | |